The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.
Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.
What was tested
Treatment tested
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
What it measured
Main measures
Change in microglia-activity in RRMS patients on teriflunomide treatment as measured by PET imaging and [11C]PK11195 radioligand.
Smouldering inflammation
Other measures (1)
Comparison of the following MRI parameters
MRI lesions
Loading reviews and guidelines…
Related trials
- CALLIPER
Phase 2 · Status unknown
No result found
- CALLIPER study
Phase 2 · Moved to EU CTIS registry
- STOP-I-SEP
Phase 3 · Running, not recruiting
Still running
- TERIPET
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Feb 2017
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error